SeaStar Medical Holding Corp 8K

SeaStar Medical reported strong growth in QUELIMMUNE pediatric AKI revenue, advanced its pivotal adult AKI trial, and obtained ICD-10-PCS billing codes for its SCD therapy while incurring a higher net loss and cash burn for the quarter ended June 30, 2026.

On August 12, 2025, SeaStar Medical Holding Corporation (Nasdaq: ICU) reported its financial results for the quarter ended June 30, 2026, highlighting 82% year-over-year growth in QUELIMMUNE pediatric AKI product revenue to approximately $0.6 million driven by three additional top-rated children’s hospitals, progress in enrolling 223 of 339 patients in the NEUTRALIZE-AKI pivotal adult AKI trial, and receipt of dedicated ICD-10-PCS codes from CMS effective October 1, 2026 to support standardized inpatient billing for its Selective Cytopheretic Device (SCD) therapies, while also disclosing a quarterly net loss of about $3.7 million and a reduction in cash to $7.0 million as it invests in clinical development and commercialization.

Filing Facts

CIK

1831868

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-027314

Alert Tier

6